At ICE Bioscience, we provide end-to-end biomarker discovery and detection services designed to accelerate drug development and enhance therapeutic decision-making. From sample collection and processing to biomarker validation and quantification, our advanced platforms and scientific expertise ensure the accurate identification of critical biomarkers. Whether you're in early-stage discovery or clinical development, our services support robust, data-driven insights for drug efficacy, safety assessment, and patient stratification.
Partnering with us means gaining access to cutting-edge technologies that streamline your biomarker pipeline, delivering actionable results to advance your programs efficiently and confidently.
Download our brochure here.
Species: Human, mouse, rat, dog, rabbit, monkey.
Health Status: Healthy vs. disease-state samples.
Sample Types: Blood, serum, plasma, tissue biopsies, urine, cerebrospinal fluid (CSF), PBMCs.
Processing: Isolation of key components (cells, plasma, proteins).
Storage: Optimal conditions (e.g., cryopreservation) to preserve biomarker stability.
Platform Selection: High-throughput screening, genomics, proteomics, or epigenetics platforms.
Technologies: qPCR, sequencing, LC-MS/MS, JESS, ELISA, MSD, etc.
Validation: Confirmation of identity, specificity, and reproducibility.
Quantification: Multiplex assays (MSD, AlphaLISA, HTRF), Western Blot, and others.
Flow cytometry, IncuCyte, or High-Content Analysis to assess cellular responses.
Non-invasive imaging of biomarkers in live animal models to monitor disease progression.
Statistical Analysis: Identifying trends and correlations.
Interpretation: Results contextualized for therapeutic or biological processes.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
